View Clinical Trial (Medical Research Study)
Temporal Behavior of Coagulation Factors,Cytokines and Tissue Injury Markers in Sepsis: Validation of Extracellular Histones
| City: |
|
Oklahoma City |
| State: |
|
Oklahoma |
| Zip Code: |
|
73104 |
| Conditions: |
|
Sepsis |
| Purpose: |
|
In an effort to better understand the interaction between the different mediators, the
investigators propose to examine the time course of mediators, the indexes of organ injury
and the coagulation cascade.
|
| Study Summary: |
|
All patients admitted to the ICU (Including VA Medical Center, University Hospital and
Presbyterian hospital) will be screened for enrollment in the study. Patients who have the
diagnosis of sepsis will be asked to volunteer. We will match sepsis patients with other ICU
patients without the diagnosis of sepsis. The latter will also be asked to volunteer.
Patients will be stratified into three groups:
- Sepsis
- SIRS of non-septic origin
- Other ICU patients
Routine laboratory data and clinical data (see flow sheet) will be collected. The plasma or
serum will be frozen separately until the target number of patients is met. Measurements of
inflammatory mediators and other cytokines/injury markers will be carried out at that point.
|
| Criteria: |
|
Inclusion Criteria:
- Admission to the ICU
Exclusion Criteria:
- No blood draws scheduled
- Hemoglobin level < 6.5 gm/dl
|
| NCT ID: |
|
NCT01012115 |
| Primary Contact: |
|
Principal Investigator
Gary T Kinasewitz, MD
OU Health Sciences Center
Gary T Kinasewitz, MD
Phone: 405-271-6173 ext. 6
Email: gary-kinasewitz@ouhsc.edu
|
| Backup Contact: |
|
Email: priscilla-peer@ouhsc.edu
Priscilla Peer, BS
Phone: 405-271-6173 ext. 6
|
| Location Contact: |
|
Oklahoma City, Oklahoma 73104
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|